Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI granted patent on synthetic antibodies in the EU
PHI announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office.
Directed issue registered at the Companies Registration Office
PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 15 november 2023
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on November 15, 2023. The following resolutions were passed at the meeting.
BioStock: PHI’s CEO reflects on the Company’s momentum
BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
BioStock: Altium fuels PHI’s forward drive
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.
Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ) held its annual general meeting on the 27th of October 2023. At the general meeting, the following resolutions were made.
Major shareholder acquires PHI’s convertible loan from Formue Nord
PHI informs the market that PHI’s largest investor, Altium S.A., has on this day taken over PHI’s outstanding convertible loan from Formue Nord.
PHI’s Board of Directors proposes signing Altium as global distributor partner
PHI’s Board of Directors decided to propose signing Altium S.A., which also is the Company’s largest shareholder, as a global PHI distributor partner.
PHI’s Board of Directors proposes a Direct Issue of shares of 9.9 MSEK to Altium
PHI’s Board of Directors proposes a direct issue of 2 374 820 new shares to the Company’s largest shareholder, Altium S.A.
PHI endorses WFIRM as Finalist for NSF’s $160 Million Innovation Grant
PHI proudly stands behind the Wake Forest Institute for Regenerative Medicine (WFIRM) as they contend as a finalist in the National Science Foundation’s (NSF) Regional Innovation Engines competition, with a potential award of up to $160 million.